Archive: News

  • Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer

    In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.

    Category: News

  • Indivumed Global Alliance to Broaden Access to Multi-Omics Algorithms, Precision Medicine Education

    Germany-based Indivumed is enlisting the help of cancer centers and research institutions around the world to help expand its omics database and make it a key resource for unraveling the complexities of cancer biology and advancing new precision oncology drugs. Indivumed last month launched the Oncology Alliance for Individualized Medicine (Onco AI-Med), which is a partnership between leading cancer clinics and research institutions selected based on their research activities and expertise in molecularly informed cancer care.

    Category: News

  • Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit

    We are in unprecedented times requiring us to approach our medical obligations in unprecedented ways. Cancer care is not elective and therefore must be maintained throughout the COVID-19 pandemic. However, we recognize that there is early evidence based on small studies from China and Italy that cancer patients are at increased risk of severe illness if they are to develop a COVID-19 infection and there is even some evidence to suggest that healthcare providers are at increased risk, possibly due to exposure to larger viral loads and repeated exposure…

    Category: News

  • FDA Approves Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma

    “The approval of nivolumab and ipilimumab in the second-line treatment of advanced HCC means we will have a combination immune therapy option in patients who have progressed on frontline therapy. The overall survival (OS) of nivolumab and ipilimumab in the second-line treatment of advanced HCC as shown in CheckMate-040 was very promising, so far the longest duration of OS in the second-line setting for advanced-stage HCC, tested in clinical trials,” said Aiwu Ruth He, MD, PhD, associate professor of Medical Oncology at Georgetown University.

    Category: News

  • Targeted Therapies Showing Promise in Colorectal Cancer

    Benjamin Weinberg, MD, assistant professor of medicine and attending physician at MedStar Georgetown University Hospital, Washington, DC, discusses novel agents that may impact the treatment landscape for colorectal cancer (CRC) once made available in the community setting.

    Category: News

  • Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer

    In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.

    Category: News

  • Understanding the Microbiome and its Effect on Treatment of Patients with Colorectal Cancer

    In an interview with Targeted Oncology at the 2019 Ruesch Center Symposium, Weinberg shared key points from his discussion on mining the microbiome in patients with CRC and summarized the treatment landscape for patients with metastatic disease. He also discussed an upcoming basket trial that uses liquid biopsies to place patients on treatment plans that will be most effective for their individual needs.

    Category: News

  • Scientific Presentations at 2019 Ruesch Symposium Inspire

    The 10th Annual Ruesch Symposium provided a forum for discussions on cutting-edge research and the pipeline of promising new therapies and technologies in GI cancers.

    Category: News

  • Does the tumor microbiome play a role in early-onset colorectal cancer?

    The human body is composed of around a trillion cells, and there are a trillion to a trillion-and-a-half bacterial cells composing our gut microbiome. Of these bacteria, some are good and help us digest foods. Others can behave badly and are associated with diseases such as autoimmunity and cancer.

    Category: News

  • The Quest for a Cure: Cancer Expert John Marshall ’79 on Battling the Disease in His Work and His Family

    Dr. John Marshall was recently the keynote “Faces of Cancer” event at his alma mater, the Episcopal High School in Alexandria VA. He shared his personal experiences with cancer and discussed myths about the disease, the economics of treatment, and his work to advance genetics-driven precision medicine.

    Category: News